Anti-S13A2/ SLC13A2/ NADC1 monoclonal antibody

Anti-S13A2/ SLC13A2/ NADC1 antibody for FACS & in-vivo assay

Target products collectionGo to SLC13A2/SLC13A2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1537-Ab-1/ GM-Tg-hg-MP1537-Ab-2Anti-Human SLC13A2 monoclonal antibodyHuman
GM-Tg-rg-MP1537-Ab-1/ GM-Tg-rg-MP1537-Ab-2Anti-Rat SLC13A2 monoclonal antibodyRat
GM-Tg-mg-MP1537-Ab-1/ GM-Tg-mg-MP1537-Ab-2Anti-Mouse SLC13A2 monoclonal antibodyMouse
GM-Tg-cynog-MP1537-Ab-1/ GM-Tg-cynog-MP1537-Ab-2Anti-Cynomolgus/ Rhesus macaque SLC13A2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1537-Ab-1/ GM-Tg-felg-MP1537-Ab-2Anti-Feline SLC13A2 monoclonal antibodyFeline
GM-Tg-cang-MP1537-Ab-1/ GM-Tg-cang-MP1537-Ab-2Anti-Canine SLC13A2 monoclonal antibodyCanine
GM-Tg-bovg-MP1537-Ab-1/ GM-Tg-bovg-MP1537-Ab-2Anti-Bovine SLC13A2 monoclonal antibodyBovine
GM-Tg-equg-MP1537-Ab-1/ GM-Tg-equg-MP1537-Ab-2Anti-Equine SLC13A2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1537-Ab-1/ GM-Tg-hg-MP1537-Ab-2; GM-Tg-rg-MP1537-Ab-1/ GM-Tg-rg-MP1537-Ab-2;
GM-Tg-mg-MP1537-Ab-1/ GM-Tg-mg-MP1537-Ab-2; GM-Tg-cynog-MP1537-Ab-1/ GM-Tg-cynog-MP1537-Ab-2;
GM-Tg-felg-MP1537-Ab-1/ GM-Tg-felg-MP1537-Ab-2; GM-Tg-cang-MP1537-Ab-1/ GM-Tg-cang-MP1537-Ab-2;
GM-Tg-bovg-MP1537-Ab-1/ GM-Tg-bovg-MP1537-Ab-2; GM-Tg-equg-MP1537-Ab-1/ GM-Tg-equg-MP1537-Ab-2
Products NameAnti-SLC13A2 monoclonal antibody
Formatmab
Target NameSLC13A2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SLC13A2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species S13A2/ SLC13A2/ NADC1 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1537
    Target NameSLC13A2
    Gene ID9058,20500,65202,715895,491167,101099847,505069,100072053
    Gene Symbol and SynonymsmNaDC-1,mucin,NaCT,NaDC-1,NADC1,SDCT1,SLC13A2
    Uniprot AccessionQ13183,P70545
    Uniprot Entry NameS13A2_HUMAN,S13A2_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000007216
    Target ClassificationN/A

    The target: SLC13A2, gene name: SLC13A2, also named as NADC1, NaCT, NaDC-1, SDCT1. The protein encoded by this gene is a sodium-coupled citrate transporter that is regulated by the chaperone activity of cyclophilin b. The encoded protein may play a role in the formation of kidney stones. [provided by RefSeq, Oct 2016].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.